e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
Date of Report (Date of earliest event reported)
  May 2, 2006
 
   
Targeted Genetics Corporation
 
(Exact name of registrant as specified in its charter)
         
Washington   0-23930   91-1549568
 
(State or other jurisdiction
of incorporation) 		  (Commission File
Number) 		  (IRS Employer
Identification No.)
         
1100 Olive Way, Suite 100, Seattle, Washington
    98101  
 
(Address of principal executive offices)
  (Zip Code)
     
Registrant’s telephone number, including area code
   (206) 623-7612
 
    
Not Applicable
 
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 2.02. Results of Operations and Financial Condition.
     On May 2, 2006, Targeted Genetics announced preliminary financial results for the quarter ended March 31, 2006. A copy of the press release related to this announcement is attached as Exhibit 99.1 and is incorporated into this current report by reference.
Item 9.01. Financial Statements and Exhibits.
     Exhibits.
         
  99.1    
Press Release of Targeted Genetics Corporation dated May 2, 2006
SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
    Targeted Genetics Corporation
 
        
 
  By:        /s/ David J. Poston
 
       
 
           David J. Poston
     VP Finance, Chief Financial Officer and
     Treasurer
Dated: May 2, 2006

2

 

INDEX TO EXHIBITS
         
Exhibit    
Number   Description
       
 
  99.1    
Press Release of Targeted Genetics Corporation dated May 2, 2006

3